InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,427.13
(
-2.31%
)
US TECH 100
18,606.40
(
-3.22%
)
Dow Jones
39,853.87
(
-1.25%
)
Brent Oil
80.74
(
-0.05%
)
Bitcoin
65,360.34
(
-0.82%
)
Post# of 252666
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 120111
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 117068

Saturday, 03/26/2011 1:48:08 PM

Saturday, March 26, 2011 1:48:08 PM

Post# of 252666
MNTA—I would suggest that your experience with ZGEN has colored your view of biotech buyouts and that, as a result, you’re now painting with too broad a brush. A key distinction between ZGEN and MNTA is that the former had a dominant shareholder (Novo Nordisk) while the latter does not.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up